(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

162162

(43) International publication date
2 September 2004 (02.09.2004)

PCT

(10) International publication number
WO 2004/073696 A1

(51) International patent classification[7]: A61K 9/70

(21) International application number: PCT/EP2004/001052

(22) International filing date: 4 February 2004 (04.02.2004)

(25) Language of filing: German

(26) Language of publication: German

(30) Data relating to the priority:
03 003 888.9 21 February 2003 (21.02.2003) EP
03 004 061.2 25 February 2003 (25.02.2003) EP

(71) Applicant *(for all designated States except US)*: SCHERING AG [DE/DE]; Müllerstrasse 170-178, 13353 Berlin (DE).

(72) Inventors; and
(75) Inventors/Applicants *(US only)*: SCHUMACHER, Jochen [DE/DE]; Im Krautgarten 13, 07751 Bucha (DE). SÜSSE, Manfred [DE/DE]; Dorfstrasse 6, 07381 Langenorla (DE). DITTGEN, Michael [DE/DE]; Heidenberg 35, 99510 Apolda (DE). MLETZKO, Stephan [DE/DE]; Sportforumstrasse 1, 14053 Berlin (DE). INGWERSEN, Jan-Peter [DE/DE]; Im Amseltal 10, 13465 Berlin (DE). LANGGUTH, Thomas [DE/DE]; Werner-Seelenbinder-Strasse 35, 07745 Jena (DE). SCHENK, Dirk [DE/DE]; Ostenerfeldweg 5a, 83623 Dietramszell (DE). KAFFL, Hubert [DE/DE]; Hagnberg 1, 83730 Fischbachau (DE).

(81) Designated states *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated states *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
- *With International Search Report.*
- *Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For an explanation of the two-letter codes and the other abbreviations, reference is made to the explanations ("Guidance Notes on Codes and Abbreviations") at the beginning of each regular edition of the PCT Gazette.

As printed

G00002

(54) Title: UV STABLE TRANSDERMAL THERAPEUTIC PLASTER

(54) Bezeichnung: UV-STABILES TRANSDERMALES PFLASTER

(57) Abstract: The invention relates to a UV stable transdermal therapeutic system (TTS) consisting of a back layer, at least one matrix containing an active substance and, optionally, a withdrawal film and an UV-radiation absorber. An adhesive layer containing said UV-radiation absorber is arranged between the back layer and the matrix containing an active substance which is distant as much as possible from a surface, a separation layer is arranged between the adhesive layer containing said UV-radiation absorber and the matrix containing an active substance, which is as remote as possible from the surface which is impermeable to the active substance and UV radiation absorber. The inventive transdermal therapeutic system exhibits a high stability and is devoid of inconveniences of existing TTS containing a light-sensitive substance.

(57) Zusammenfassung: Die Erfindung betrifft ein neues UV-stabiles transdermales therapeutisches System (TTS), welches aus einer Rückschicht, mindestens einer wirkstoffhaltigen Matrix und wahlweise einer Abziehfolie besteht sowie einen UV-Absorber enthält, wobei zwischen der Rückschicht und der der Hautoberfläche am weitesten abgewendeten wirkstoffhaltigen Matrix mindestens eine UV-Absorber enthaltende Klebschicht vorgesehen ist und zwischen der den UV-Absorber enthaltenden Klebschicht und der der Hautoberfläche am weitesten abgewendeten wirkstoffhaltigen Matrix mindestens eine Trennschicht enthalten ist, die wirkstoffundurchlässig und für den UV-Absorber undurchlässig ist. Das erfindungsgemässe transdermale therapeutische System realisiert eine hohe Stabilität ohne die Nachteile herkömmlicher lichtempfindliche Wirkstoffe enthaltende TTS.

WO 2004/073696 A1